Dynamics of within-host *Mycobacterium tuberculosis* diversity and heteroresistance during treatment

[Supplementary Methods 2](#_Toc33778128)

[Supplementary Tables 5](#_Toc33778129)

[Supplementary Figures 12](#_Toc33778130)

[References 19](#_Toc33778131)

## Supplementary Methods

**Supplementary Methods 1: Phenotypic drug susceptibility testing drugs and critical concentration****s**

Phenotypic drug susceptibility testing (pDST) was performed on Middlebrook 7H11 agar for the following drugs at the specified critical concentrations below. These are based on World Health Organization (WHO) approved critical concentrations where possible(1) but differ in some instances where evidence is limited or for legacy reasons within our laboratory.

|  |  |  |
| --- | --- | --- |
| Drug | Critical concentration (μg/mL) | WHO critical concentration (μg/mL) |
| Rifampicin | 1.0 | Same |
| Isoniazid | 0.2 (low) / 1.0 (high) | Same |
| Ethambutol | 7.5 | Same |
| Ofloxacin | 2.0 | Not set |
| Moxifloxacin | 0.5 | Same |
| Kanamycin | 5.0 | Not set |
| Bedaquiline | 0.25 | Same |
| Clofazimine | 0.25 | Not set |
| Capreomycin | 10.0 | Not set |
| Ethionamide | 5.0 | 10.0 |
| p-aminosalicylic acid | 2.0 | Not set |

**Supplementary Methods 2: Method for DNA extraction**

Sputum samples were decontaminated, homogenised and inoculated into mycobacterial growth indicator tubes (MGIT) and incubated in a BACTEC MGIT 960 (BD, NJ, USA) until flagging positive. Positive MGIT tubes were centrifuged at 16,000g for 15 minutes and the supernatant removed. Cells were resuspended in phosphate-buffered saline before undergoing heat killing at 95°C for 1 hour followed by centrifugation at 16,000g for 15 minutes. The supernatant was removed and the sample resuspended in 1mL sterile saline (0.9% w/v). Centrifugation, removal of supernatant and resuspension in 1mL sterile saline was repeated. DNA was extracted with mechanical ribolysis before purification with AMPure XP beads (Beckman Coulter, IN, USA). DNA concentrations were measured with Qubit (ThermoFisher, MA, USA). NEBNext Ultra II DNA (New England Biolabs, MA, USA) was used for DNA library preparation. Batches of 48 multiplexed samples were sequenced on NextSeq 500 (Illumina, CA, USA) 300-cycle paired end runs with a mid-output kit.

**Supplementary Methods 3: Genetic mutations conferring drug resistance**

|  |  |
| --- | --- |
| First line drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) | Walker et al (2) |
| Second line drugs (all others) | Phelan et al (3) |

The following additional mutations were included:

|  |  |  |
| --- | --- | --- |
| **Gene** | **Drug** | **Variant** |
| *atpE* | Bedaquiline | D28A |
| *atpE* | Bedaquiline | D28G |
| *atpE* | Bedaquiline | D28N |
| *atpE* | Bedaquiline | D28P |
| *atpE* | Bedaquiline | D28V |
| *atpE* | Bedaquiline | L59V |
| *atpE* | Bedaquiline | E61D |
| *atpE* | Bedaquiline | A63P |
| *atpE* | Bedaquiline | A63V |
| *atpE* | Bedaquiline | I66M |
| *Rv0678* | Bedaquiline/Clofazimine | any non-synonymous/frameshift - evaluated individually |
| *pepQ* | Bedaquiline/Clofazimine | A14fs |
| *pepQ* | Bedaquiline/Clofazimine | L44P |
| *pepQ* | Bedaquiline/Clofazimine | R271fs |
| *Rv1979c* | Clofazimine | V52G |
| *Rv1979c* | Clofazimine | V351A |
| *fgd1* | Delaminid | G49fs |
| *fbiA* | Delaminid | D49Y |
| *ddn* | Delaminid | G81D |
| *ddn* | Delaminid | G81S |
| *rplC* | Linezolid | T460C |
| *rrl* | Linezolid | c1921t |
| *rrl* | Linezolid | g2061t |
| *rrl* | Linezolid | g2270c/t |
| *rrl* | Linezolid | g2294a |
| *rrl* | Linezolid | g2299t |
| *rrl* | Linezolid | g2447t |
| *rrl* | Linezolid | g2576t |
| *rrl* | Linezolid | g2576t |
| *rrl* | Linezolid | a2689t |
| *rrl* | Linezolid | g2746a |
| *rrl* | Linezolid | a2810c/t |
| *rrl* | Linezolid | g2814t |
| *rrl* | Linezolid | c2848a |

## Supplementary Tables

Supplementary Table 1. Genomic regions covered by resistance bait set for deep sequencing. Resistance conferred lists whether the genomic region is proposed to confer resistance to one or more specific drugs, or is an efflux pump that has the potential to be involved in resistance to multiple drugs. Some variable and housekeeping genes identified from previous studies are also included.

|  |  |  |  |
| --- | --- | --- | --- |
| **NC\_000962.3 coordinate** | | **Description** | **Resistance conferred** |
| **Start** | **End** |
| 5139 | 9918 | *gyrB...gyrA* | Fluoroquinolones |
| 53562 | 55799 | *ponA1* | Rifampicin |
| 125542 | 130641 | *ctpI* | Variable gene |
| 222188 | 223630 | *Rv0191* | Efflux pump |
| 244383 | 247418 | *mmpl3* | mmpL3 inhibitors |
| 409261 | 414338 | *iniB…iniC* | Isoniazid |
| 490682 | 491893 | *fgd1* | Delamanid |
| 575247 | 576890 | *mshA* | Ethionamide |
| 629939 | 631786 | *Rv0538* | Variable gene |
| 650678 | 651604 | *Rv0560c* | DprE1 inhibitors |
| 759706 | 767420 | *rpoB…rpoC* | Rifampicin |
| 775485 | 779587 | *mmpL5…Rv0678* | Bedaquiline/Clofazimine |
| 781459 | 782034 | *rpsL* | Streptomycin |
| 800708 | 802233 | *rplC…rplD* | Linezolid |
| 814227 | 815090 | *rpsE* | Unknown |
| 840846 | 841756 | *vapB31…vapC31* | Variable genes |
| 945955 | 947415 | *Rv0849* | Streptomycin/Kanamycin |
| 1010035 | 1011834 | *Rv0907* | Variable gene |
| 1302830 | 1305601 | *fbiC* | Delamanid |
| 1313624 | 1315291 | *pks3* | Variable gene |
| 1361697 | 1362833 | *Rv1218c* | Streptomycin/Kanamycin |
| 1405980 | 1407440 | *Rv1258c* | Streptomycin/Kanamycin |
| 1416080 | 1417447 | *embR* | Ethambutol |
| 1460944 | 1461390 | *atpE* | Bedaquiline |
| 1471745 | 1476895 | *rrs…rrl* | Injectables |
| 1480793 | 1482601 | *Rv1319c* | Variable gene |
| 1586109 | 1587866 | *Rv1410c* | Efflux pump |
| 1624353 | 1625465 | *opcA* | Variable gene |
| 1673299 | 1675111 | *fabG1\_promoter* | Isoniazid/Ethionamide |
| 1833441 | 1835087 | *rpsA* | Pyrazinamide |
| 1893476 | 1894330 | *Rv1667c* | Efflux pump |
| 1917839 | 1918846 | *tlyA* | Capreomycin |
| 1929685 | 1931556 | *cycA* | Cycloserine |
| 2101550 | 2103142 | *ndh* | Clofazamine/Ethionamide |
| 2153788 | 2156211 | *katG* | Isoniazid |
| 2156048 | 2156692 | *furA* | Isoniazid |
| 2221618 | 2223264 | *Rv1979c* | Clofazamine |
| 2231579 | 2232319 | *erm(37)* | Macrolides |
| 2288580 | 2289341 | *pncA* | Pyrazinamide |
| 2294430 | 2307086 | *pks12* | Variable gene |
| 2338608 | 2340974 | *Rv2082* | Variable gene |
| 2414833 | 2416494 | *murD* | Variable gene |
| 2434536 | 2434847 | *Rv2172c-idsA2* | Capreomycin |
| 2518014 | 2519465 | *kasA* | Isoniazid |
| 2714023 | 2715432 | *eis* | Kanamycin |
| 2725470 | 2726880 | *oxyR…ahpC* | Isoniazid |
| 2733129 | 2734244 | *rbsK* | Variable gene |
| 2746034 | 2747698 | *folC* | PAS |
| 2859199 | 2860518 | *pepQ* | Bedaquiline |
| 2866367 | 2867886 | *lppA…lppB* | Variable genes |
| 2881308 | 2882247 | *Rv2561* | Variable genes |
| 2986738 | 2987715 | *ribD* | PAS |
| 3004644 | 3005750 | *Rv2688c* | Efflux pump |
| 3017734 | 3019521 | *sigA* | Housekeeping gene |
| 3022360 | 3023532 | *sigB* | Housekeeping gene |
| 3067945 | 3068188 | *thyX-hsdS.1* | PAS |
| 3073579 | 3074571 | *thyA* | PAS |
| 3086719 | 3088035 | *ald* | Cycloserine |
| 3129243 | 3131873 | *Rv2823c* | Variable gene |
| 3152938 | 3154731 | *efpA* | Efflux pump |
| 3196330 | 3196950 | *Rv2887* | DprE1 inhibitors |
| 3245344 | 3251175 | *ppsA* | Variable gene |
| 3272113 | 3273309 | *drrA* | Efflux pump |
| 3336695 | 3338017 | *ddlA* | Cycloserine |
| 3366543 | 3367367 | *Rv3008* | Efflux pump |
| 3430286 | 3430810 | *mmr* | Streptomycin/Kanamycin |
| 3448403 | 3450091 | *Rv3083* | Ethionamide |
| 3511317 | 3511681 | *PPE52-nuoA* | Unknown |
| 3568300 | 3568779 | *whiB7* | Streptomycin/Kanamycin |
| 3624809 | 3626713 | *mtrB* | Variable gene |
| 3640442 | 3642981 | *fbiA…fbiB* | Delamanid |
| 3840093 | 3841520 | *alr* | Cycloserine |
| 3986743 | 3987399 | *ddn* | Delamanid |
| 4007230 | 4008282 | *nat* | PAS |
| 4043761 | 4044381 | *panD* | Pyrazinamide |
| 4155639 | 4156829 | *dnaQ* | Variable gene |
| 4201793 | 4202713 | *proZ* | Efflux pump |
| 4235678 | 4237264 | *dprE1* | DprE1 inhibitors |
| 4239762 | 4249910 | *embC…embB* | Ethambutol |
| 4268824 | 4269933 | *ubiA* | Ethambutol |
| 4325903 | 4328299 | *ethA…ethR* | Ethionamide |
| 4407427 | 4408302 | *gid* | Streptomycin |

Supplementary Table 2. Associations between mixed infection and patient and bacterial factors.

|  |  |  |
| --- | --- | --- |
| Characteristic | Number (%) | p-value (no. in category) |
| PATIENT FACTORS | | |
| Age Category  <25  25-30  30-35  35-40  40-50  ≥50 | 1/32 (3.03%)  5/68 (7.35%)  8/71 (11.27%)  4/54 (7.41%)  1/73 (1.37%)  2/47 (4.26%) | 0.195  N=346 |
| Sex  Male  Female | 15/203 (7.39%)  6/143 (4.20%) | 0.221  N=346 |
| Previous TB  No  Yes | 11/178 (6.18%)  10/165 (6.06%) | 0.963  N=343 |
| HIV status  No  Yes | 6/66 (9.09%)  15/283 (5.30%) | 0.244  N=349 |
| CD4 count  ≥200  <200 | 6/96 (6.25%)  2/109 (1.83%) | 0.103  N=205 |
| Taking antiretroviral therapy  No  Yes | 5/104 (4.81%)  9/185 (4.86%) | 0.983  N=289 |
| Cavitation on chest radiography  No  Yes | 4/93 (4.30%)  2/28 (7.14%) | 0.544  N=121 |
| On TB treatment at enrolment  No  Yes | 11/164 (6.71%)  10/180 (5.56%) | 0.656  N=344 |
| BACTERIAL FACTORS | | |
| DR profile  DS  MDR/RR  Pre-XDR/XDR | 6/89 (6.74%)  12/192 (6.77%)  2/71 (2.82%) | 0.456  N=352 |

Supplementary Table 3. Correlates of month six outcome showing hazard ratio and 95% confidence intervals (95% CI) and p-values calculated by logistic regression. All hazard ratios refer to patients with single strain infection, except for the hazard ratio for mixed infection.

|  |  |  |
| --- | --- | --- |
| Characteristic | Hazard ratio (95% CI) | p-value |
| PATIENT FACTORS | | |
| Age (per year increment) | 1.02 (0.99-1.04) | 0.2561 |
| Male sex | 1.97 (1.11-3.48) | 0.0189 |
| Positive HIV status | 3.78 (1.31-10.94) | 0.0043 |
| CD4 count ≥200 | 0.56 (0.27-1.18) | 0.1278 |
| Taking antiretroviral therapy | 2.55 (1.21-5.38) | 0.0090 |
| Previous TB | 1.41 (0.80-2.50) | 0.2331 |
| Cavitation on chest radiography | 0.63 (0.17-2.39) | 0.4859 |
| On TB treatment at enrolment | 0.51 (0.29-0.90) | 0.0184 |
| BACTERIAL FACTORS | | |
| Mtb lineage 2 (v lineage 4) | 0.98 (0.54-1.79) | 0.9602 |
| Drug resistance profile (v DS)  MDR/RR  Pre-XDR/XDR | 1.62 (0.77-3.42)  2.42 (1.04-5.59) | 0.204  0.039 |
| Mixed infection | 1.28 (0.45-3.69) | 0.6415 |

Supplementary Table 4. Classification, description and nucleotide diversity (π) of the 10 most diverse coding genes in baseline sequences.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gene | Classification | Functional category | Functional description | π |
| *Rv1319c* | Non-Essential | intermediary metabolism and respiration | Probable adenylate cyclase | 2.65 ×10-4 |
| *Rv3424c* | Non-Essential | conserved hypotheticals | Unknown | 2.55 ×10-4 |
| *Rv2825c* | Non-Essential | conserved hypotheticals | Unknown | 1.51 ×10-4 |
| *Rv1435c* | Non-Essential | cell wall and cell processes | Unknown | 1.07 ×10-4 |
| *Rv2319c* | Essential | virulence, detoxification, adaptation | Unknown | 9.26 ×10-5 |
| *cysA2* | Non-Essential | intermediary metabolism and respiration | Sulfotransferase | 7.41 ×10-5 |
| *fadD18* | Non-Essential | lipid metabolism | Lipid degradation | 7.39 ×10-5 |
| *Rv2081c* | Non-Essential | cell wall and cell processes | Unknown | 6.46 ×10-5 |
| *Rv0740* | Non-Essential | conserved hypotheticals | Unknown | 5.82 ×10-5 |
| *Rv1765c* | Antigen | conserved hypotheticals | Unknown | 5.32 ×10-5 |

Supplementary Table 5. Frequencies and outcomes of baseline hetRAVs.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient ID** | **Drug** | **Mutation** | **Allele frequency** | | | | |
| **Sample 1** | **Sample 2** | **Sample 3** | **Sample 4** | **Sample 5** |
| K0045 | Rifampicin | Asp435Val | 64.1% | 42.6% |  |  |  |
| K0045 | Rifampicin | Ser450Leu | 31.3% | 56.1% |  |  |  |
| K0056 | Rifampicin | Leu430Pro | 15.4% | 77.8% | 100.0% |  |  |
| K0056 | Rifampicin | Asp435Val | 75.7% | 18.4% | 0.0% |  |  |
| K0062 | Rifampicin | Ser450Leu | 9.1% | 0.0% | 0.0% |  |  |
| K0084 | Rifampicin | His445Tyr | 7.8% | 0.0% | 0.0% |  |  |
| K0084 | Rifampicin | Ser450Leu | 92.3% | 100.0% | 100.0% |  |  |
| K0085 | Rifampicin | His445Asp | 88.6% | 100.0% | 100.0% |  |  |
| K0085 | Rifampicin | Leu452Pro | 9.1% | 0.0% | 0.0% |  |  |
| P0117 | Rifampicin | His445Tyr | 41.4% | 0.0% | 100.0% |  |  |
| P0117 | Rifampicin | His445Arg | 49.2% | 98.0% | 0.0% |  |  |
| P3418 | Isoniazid (katG) | Gly297Val | 48.5% | 11.5% |  |  |  |
| K0049 | Pyrazinamide | Thr153fs | 92.7% | 96.8% | 92.1% |  |  |
| P0037 | Pyrazinamide | Thr153fs | 91.3% | 100.0% |  |  |  |
| P0044 | Pyrazinamide | Thr153fs | 93.1% | 97.2% | 94.1% |  |  |
| P3505 | Pyrazinamide | Thr153fs | 93.6% | 96.4% |  |  |  |
| P3519 | Pyrazinamide | Thr153fs | 94.8% | 93.3% |  |  |  |
| P3535 | Pyrazinamide | Thr153fs | 93.3% | 97.0% |  |  |  |
| K0006 | Ethambutol | Asp328Tyr | 43.9% | 0.0% | 0.0% |  |  |
| P0027 | Fluoroquinolones | Glu501Asp | 30.0% | 14.0% | 5.6% | 61.7% | 51.7% |
| P0027 | Fluoroquinolones | Ala90Val | 39.1% | 36.5% | 91.3% | 10.7% | 0.0% |
| P0027 | Fluoroquinolones | Asp94Gly | 28.4% | 42.9% | 0.0% | 0.0% | 33.9% |
| P0117 | Fluoroquinolones | Asn499Tyr | 33.9% | 0.0% | 100.0% |  |  |
| P0117 | Fluoroquinolones | Ala90Val | 14.7% | 0.0% | 0.0% |  |  |
| P0117 | Fluoroquinolones | Asp94Gly | 47.9% | 100.0% | 0.0% |  |  |
| P0040 | Second line injectables | Ala67fs | 88.2% | 94.4% |  |  |  |
| P0027 | Bedaquiline | Arg109Leu | 75.4% | 92.3% | 94.3% | 22.5% | 31.3% |
| P0027 | Bedaquiline | Arg156fs | 12.9% | 7.8% | 8.1% | 54.1% | 30.2% |
| P0150 | Bedaquiline | Glu49fs | 72.1% | 96.1% | 96.9% |  |  |
| P3427 | Bedaquiline | Met146Thr | 2.0% | 0.0% |  |  |  |

## Supplementary Figures



Supplementary Figure 1. Nucleotide diversity median and interquartile range stratified by number of PCR cycles during library preparation. Outlying values are marked with circles. We observed no statistically significant difference between any of the four classes (equality of medians test).



Supplementary Figure 2. Scatter plot and linear regression line of proportion of *k*-mers assigned to *Mycobacteria* by Kraken2 and nucleotide diversity. R-squared 0.6%, p=0.16 for linear association using linear regression.



Supplementary Figure 3. Nucleotide diversity stratified by sample culture media: MGIT (initial culture), 7H9 (single subculture), 7H11 (solid plate) or unknown. We observed no statistically significant difference between any of the culture media (Wilcoxon rank-sum test).



Supplementary Figure 4. Linear regression of increasing smear grade level against nucleotide diversity with fitted regression line. R-squared 0.3%, p=0.43 for linear association using linear regression.

**

Supplementary Figure 5. Association between increasing MGIT time to positivity (TTP) and nucleotide diversity with fitted linear regression. R-squared 1.8%, p=0.017 for linear association using linear regression.



Supplementary Figure 6. Box plot showing median and interquartile range of nucleotide diversity in sequential samples from patients who had at least one positive culture after week 2 at timepoints where there were ≥5 samples. Dots mark outlying values. Numbers indicate number of isolates at each timepoint. Bars indicate where distributions are statistically significantly different from baseline, with p-values calculated by Wilcoxon rank-sum test.



Supplementary Figure 7. Box plot showing median and interquartile range of nucleotide diversity in sequential isolates from patients who were not receiving any TB treatment at the time of enrolment. There were no statistically significant differences between timepoints (Wilcoxon rank-sum test).

## References

1. World Health Organization. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. Geneva; 2018.

2. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med [Internet]. 2018 Sep 26;379(15):1403–15. Available from: https://doi.org/10.1056/NEJMoa1800474

3. Phelan JE, O’Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med. 2019;11(1).